Linagliptin Farmak (Linagliptin)

• Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus.
• Type 2 diabetes mellitus: improves glycaemic control as part of a comprehensive diabetes management plan.
• Adjunct to diet and exercise: used together with lifestyle measures to lower blood glucose levels.
• Combination therapy: added to metformin or other oral antidiabetics when glycaemic targets are not met.
• Monotherapy in patients intolerant to other agents: provides glucose‑lowering effect without weight gain.

• Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, linagliptin increases endogenous incretin concentrations, enhancing glucose‑dependent insulin secretion from pancreatic β‑cells and suppressing glucagon release from α‑cells, thereby lowering post‑prandial and fasting plasma glucose levels. The effect is glucose‑dependent, minimizing risk of hypoglycaemia when used alone, and the drug is excreted largely unchanged via the bile, requiring no dose adjustment in renal impairment.

Linagliptin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nose and throat.
• Headache: transient head pain.
• Upper respiratory tract infection: symptoms such as cough and sore throat.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Hepatic injury: abnormal liver function tests or jaundice.

• When prescribing linagliptin, clinicians should consider several precautionary measures to ensure patient safety.
• Renal function: assess baseline renal function and monitor periodically, although dose adjustment is not required.
• Hepatic function: evaluate liver enzymes before initiation and during therapy.
• Pancreatitis risk: advise patients to report persistent abdominal pain or vomiting.
• Elderly patients: monitor for dizziness and hypoglycaemia when combined with other agents.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Insulin or sulfonylureas: increased risk of hypoglycaemia; avoid dose escalation.
• Rifampin: strong enzyme inducer that may markedly reduce linagliptin exposure.
• Strong P‑gp inducers (e.g., carbamazepine): may lower drug levels and diminish efficacy.

Moderate Interactions (Monitor Closely)

• Metformin: monitor renal function as combined therapy may affect renal clearance.
• ACE inhibitors: watch for additive blood pressure effects.
• Diuretics: observe electrolyte balance, especially when combined with other antihyperglycaemic agents.